Bioinformatic analysis of the role of solute carrier-glutamine transporters in breast cancer
Xin Zhao,Liang Jin,Yujie Liu,Zhenzhen Liu,Qiang Liu
DOI: https://doi.org/10.21037/atm-22-2620
IF: 3.616
2022-07-19
Annals of Translational Medicine
Abstract:Background: Breast cancer (BC) is a highly heterogeneous disease. Solute carriers (SLCs) have been involved in the tumor progression of various cancer types. This study aimed to evaluate the role of these SLC-related glutamine transporters in the prognosis of BC patients by bioinformatics analysis.Methods: This study examined the transcription and prognostic data for glutamine-related transporters in BC from Oncomine Database, which is currently the largest oncogene microarray database platform in the world. As well as Gene Expression Profiling Interactive Analysis (GEPIA), Kaplan-Meier (K-M), and cBioPortal online resources. The Tumor Immune Estimation Resource (TIMER) and GEPIA were also used to examine the relationship between SLCs and immune cell infiltration.Results: The expression levels of <i>SLC1A5, SLC3A2, SLC7A5, SLC7A8</i>, and <i>SLC38A1</i> were higher in BC tissues than normal breast tissues, but the expression level of SLC6A14 was lower. The expression levels of <i>SLC7A5, SLC7A8, SLC6A14</i>, and <i>SLC38A2</i> were related to a later clinical tumor stage. In the K-M analyses, The K-M curves revealed that patients with high <i>SLC1A5</i> expression had a poor prognosis (OS HR =1.28, 95% CI: 1.06-1.54; P=0.01). The high expression of <i>SLC3A2</i> was significantly correlated with a poor prognosis (DMFS HR =1.19, 95% CI: 1.02-1.39; P=0.027). Increased <i>SLC7A5</i> mRNA levels and decreased <i>SLC7A8</i> mRNA levels were significantly associated with a poor prognosis in terms of OS, RFS, DMFS and PPS. The high expression of <i>SLC6A14</i> was significantly correlated with a poor prognosis (PPS HR =1.35, 95% CI: 1.07-1.7; P=0.011). The high expression of SLC38A1 was correlated with a better prognosis than low expression of <i>SLC38A1</i> (RFS HR =0.84, 95% CI: 0.76-0.93; P=0.00077; DMFS HR =0.78, 95% CI: 0.67-0.91; P=0.0013). The infiltration of immune cells and their marker genes were associated with <i>SLC1A5, SLC3A2, SLC7A5, SLC7A8, SLC6A14, SLC38A1</i>, and <i>SLC38A2</i> expression. <i>SLC7A5, SLC7A8, SLC38A1</i>, and <i>SLC38A2</i> have the potential to regulate polarization in tumor-associated macrophages.Conclusions: <i>SLC7A5, SLC7A8, SLC38A1</i>, and <i>SLC38A2</i> may regulate the polarization of tumor-associated macrophages (TAMs). <i>SLC1A5, SLC3A2, SLC7A5</i>, and <i>SLC6A14</i> may be promising biomarkers for the BC diagnosis and may represent potential therapeutic targets for these patients.
oncology,medicine, research & experimental